| Filed On | Filing |
|---|---|
| 27 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The Company held a special meeting of stockholders on October 27, 2026. The Company received proxies totaling 4,326,013 of its 9,093,871 issued and outstanding shares of common stock as of the record date of August 28, 2026. The stockhol... |
| 27 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant +3 more
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. REDACTED INFORMATION IS MARKED WITH A [***]. |
| 23 Sep 2026 | EFFECT |
| 17 Sep 2026 | FORM S-1 |
| 10 Sep 2026 | Proxy statement: special meeting on October 27, 2026 |
| 10 Sep 2026 |
8-K: Other Events
ATLANTA, GA – September 10, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against high-consequence infectious diseases and solid tumor cancers, today provided an u... |
| 31 Aug 2026 | FORM PRE 14A |
| 28 Aug 2026 | 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule |
| 28 Aug 2026 | 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 10 Aug 2026 | SCHEDULE 13G/A |
| 27 Jul 2026 | FORM 10-Q |
| 27 Jul 2026 | 8-K: Results of Operations and Financial Condition |
| 10 Jul 2026 | 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule |
| 22 Jun 2026 |
Form 4: Spencer John N Jr, Director
Granted 6,000 Stock Option |
| 22 Jun 2026 |
Form 4: Morgan Jayne, Director
Granted 6,000 Stock Option |
| 22 Jun 2026 |
Form 4: Mcnally Robert T, Director
Granted 6,000 Stock Option |
| 22 Jun 2026 |
Form 4: Lemerond Nicole, Director
Granted 6,000 Stock Option |
Loading...
